A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

• Status: Terminated
• Trial end date: 2018-10-17
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls. In addition, secondary and exploratory objectives were to assess medication adherence, healthcare utilization and costs, and patient-reported outcomes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
• Treatments: Antipsychotic Agents; Aripiprazole

Criteria

Inclusion Criteria:

• Participants are actively enrolled in an Anthem-affiliated commercial, Medicaid, or Medicare health plan with medical and pharmacy benefits.

• Participants must have a smartphone with data plan.

• Participants currently prescribed aripiprazole, or appropriate for aripiprazole treatment.

• Participants must have a current diagnosis of SCH, BP1, or MDD.

Exclusion Criteria:

• Any participant who participated in another clinical trial within 30 days of enrollment into the current study.

• Females who are breast-feeding and/or who are pregnant at the time of study enrollment, or who plan to become pregnant during the study.

• Participants who are currently being treated with a long-acting injectable antipsychotic.